165 - Effects of il6 on statin induced apoptosis in human melanoma cells

Date 28 September 2012
Event ESMO Congress 2012
Session Publication Only
Topics Basic Science
Melanoma and other Skin Tumours
Presenter Christoph Minichsdorfer
Authors C. Minichsdorfer1, C. Wasinger2, E. Sieczkowski3, B. Atil2, M. Hohenegger2
  • 1Department Of Medicine I, Medical University of Vienna, 1090 - Vienna/AT
  • 2Pharmacology, Medical University of Vienna, 1090 - Vienna/AT
  • 3Neurology, Medical University of Vienna, Vienna/AT


Statins trigger apoptosis in primary cells and tumour cells. In particular, melanoma cells have been found to be susceptible to statin-induced apoptosis, although only after longer incubation times. Cells derived from metastatic melanoma cell lines (A375, 518A2) secrete high amounts of IL-6 in contrast to WM 35 cells which derive from an early lesion. However, IL-6 did not ameliorate the statin induced apoptosis in A375 and 518A2 cells. Conversely, in WM35 cells IL-6 led to a marked decrease in Cyclin D1 levels and enhanced the simvastatin induced apoptosis. Melanoma cells from early growth stage are more resistant to simvastatin induced apoptosis than metastatic melanoma cells. IL-6 plays a major role in the progression of melanoma. Interestingly, IL-6 has no cytostatic effect on metastatic melanoma cells but primes WM 35 cells for statin induced apoptosis. These pro-apoptotic stimuli confirm possible therapeutic potentials and may guide feasibility for more potent statins in anti-cancer strategies and help to understand the dualistic effect of IL-6 during melanoma tumorigenesis. This work was supported by Herzfeldeŕsche Familienstiftung and FWF (grant P22385).


All authors have declared no conflicts of interest.